| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3981095 | Clinical Leukemia | 2006 | 5 Pages |
The bone marrow microenvironment plays a crucial role in leukemogenesis. Recent studies suggest that its vascularity changes significantly during this process and that angiogenic factors are of major importance in leukemia. This review summarizes the literature on the relationship between angiogenesis and progression of B-cell chronic lymphocytic leukemia (CLL). Accordingly, antiangiogenesis is a promising therapeutic approach in CLL. In vitro and in vivo studies have recently demonstrated the activity of lenalidomide, which has an antileukemic effect that relies on modulation of tumor microenvironment or changes in its cytokine milieu. The combination of chemotherapy and antiangiogenic agents represents a possible new way for managing patients with CLL today.
